Progyny, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 10, 2024. Progyny provides fertility benefits and an add-on pharmacy benefits solution to employers. It operates as one segment.
Financial and operating results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $278.1 million | $258.4 million | +8% |
| Gross profit / margin | $62.4 million / 22.4% | $58.6 million / 22.7% | Profit +6%; margin down 0.3 percentage points |
| Operating income / margin | $18.5 million / 6.7% | $15.0 million / 5.8% | +23% |
| Net income | $16.9 million | $17.7 million | -4% |
| Diluted EPS | $0.17 | $0.18 | Down $0.01 |
| Adjusted EBITDA (non-GAAP) | $50.3 million | $46.4 million | +8% |
| Operating cash flow | $25.7 million | $21.0 million | +$4.8 million |
Fertility benefits revenue was $169.8 million, up 8%; pharmacy benefits revenue was $108.3 million, up 7%. Management attributed growth in both solutions primarily to more clients and covered lives. Cost of services rose 8%, broadly in line with revenue, reflecting treatment, prescription and personnel costs.
Cash and cash equivalents were $115.0 million and marketable securities were $256.9 million at quarter-end. Current assets were $681.5 million versus current liabilities of $205.9 million. The balance sheet reports no borrowings; it includes operating lease liabilities of $19.3 million, of which $2.5 million is current. Q1 investing cash flow was $19.3 million, largely reflecting net proceeds from marketable securities; financing cash use was $27.4 million, primarily for share repurchases and employee tax withholding.
Changes, liquidity and notable items
- Net income declined despite higher operating income, primarily as the income tax line shifted from a $1.3 million benefit in Q1 2023 to a $5.6 million provision in Q1 2024.
- Other income, net, increased to $4.0 million from $1.3 million, primarily due to higher investment income; the period included $3.4 million of realized gains on marketable securities.
- Accounts receivable increased to $297.2 million from $241.9 million at year-end. The $60.1 million increase in receivables reduced operating cash flow, partly offset by higher accrued liabilities and lower prepaid expenses.
- Stock-based compensation was $31.1 million, compared with $30.8 million a year earlier.
- The board authorized a share repurchase program of up to $100 million in February 2024. Progyny repurchased 723,577 shares under the program during the quarter for $26.4 million, including excise taxes and trading fees, at an average $36.27 per share. Management reported $70.0 million repurchased under the program to date.
Outlook, commentary and risks
Management said existing cash, marketable securities and operating cash flow should support working capital and capital needs for at least the next 12 months. The filing refers to Q2 and full-year 2024 guidance issued May 9, 2024, but the provided filing text does not provide a clear numerical guidance value. Management cautions that quarterly results are not necessarily indicative of the full year and notes moderate seasonality, with revenue tending to be higher in the second half.
Key risks include client retention and concentration (one client contributed 11% of Q1 revenue), competition, changes in benefit utilization and treatment costs, pharmacy drug availability and pricing, and the ability to maintain provider and pharmacy networks. The filing also highlights evolving healthcare, reproductive-rights and pharmacy-benefit regulation; cybersecurity, privacy and third-party service risks; and economic conditions that could affect employer spending. Management reported disclosure controls were effective as of March 31, 2024, with no material change in internal control over financial reporting during the quarter. The company reported no legal matters it believes would have a material adverse effect.
Subsequent disclosure: On May 9, 2024, the compensation committee approved an executive severance plan. On qualifying terminations, it generally provides 12 months of base salary, a prorated bonus, subsidized COBRA and specified equity vesting; change-of-control qualifying terminations provide for full acceleration of unvested equity.
Most important facts for investors to verify
- Review the May 9, 2024 earnings release for the actual Q2 and full-year guidance figures and assumptions.
- Track receivable collections, accrued claims payable and operating cash flow as the larger client base ramps through the year.
- Assess whether revenue growth can continue while protecting gross margin, which slipped 30 basis points year over year.
- Monitor client concentration, renewals, covered-life growth and utilization; Q1 ART cycles rose to 14,802 from 13,171, while reported all-member utilization was 0.53% versus 0.54%.
- Confirm subsequent repurchase activity and remaining authorization; the filing reports $70.0 million repurchased to date under the $100 million program.
- Evaluate the potential impact of regulatory changes, reproductive-rights developments, drug supply and pricing, and data-security incidents.